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Interferon b-1a in relapsing multiple sclerosis: four-year extension of the
European IFNb-1a Dose-C omparison Study
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Dose-Comparison Study Investigatorsa
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Neurology and Neuroradiology, CH-4031 Basel, Switzerland; 3Department of Neurology, Heinrich-Heine University,
D-40225 Du¨sseldorf, Germany; 4Institute for Clinical Neuroimmunology, Ludwig-Maximilians University Munich, D-
81377 Munich, Germany
Background: Multiple sclerosis (MS) is a chronic disease requir ing long-term monito r ing o f treatment. Objective: To assess the four-
year clinical efficacy o f intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C ompar ison Study.
Methods: Patients who completed 36 months of treatment (Part 1) o f the European IFNb-1a Dose-C ompar ison Study were given the
option to continue double-blind treatment with IFNb-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were
per formed on sustained disability progression, relapses, and neutralizing antibody (NAb) formation. Results: O f 608/802 subjects who
completed 36 months o f treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and fo llow-up. IFNb-
1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses
over 48 months on any of the clinical endpo ints, including rate of disability progression, cumulative percentage of patients who progressed
(48% and 43%, respectively ), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were
positive for NAbs at any time dur ing the study was low in bo th treatment groups. Conclusion: C ompared with 60-mcg IM IFNb-1a once
weekly, a dose of 30 mcg IM IFNb-1a once weekly maintains the same clinical efficacy over four years.
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Introductio n
Three interferon beta (IFNb) products ¡/ IFNb-1b (Be-
taseron® , Berlex Laboratories Montville NJ, USA), IFNb-
1a (Avonex® , Biogen, Inc., Cambridge, MA, USA), and
IFNb-1a (Rebif® , Ares-Serono, Geneva, Switzerland) ¡/
have demonstrated beneficial effects in the treatment of
patients with relapsing multiple sclerosis (MS). Two-year
phase III pivotal trials have shown efficacy in reducing
exacerbations, slowing disability progression, and redu-
cing activity on magnetic resonance imaging (MRI).1¡ 3
However, MS is a chronic disease requiring long-term
treatment. Results of long-term follow-up patients treated
with IFNb therefore are important and should be taken
into account in clinical practice.
The efficacy and safety of intramuscular (IM) IFNb-1a
were recently evaluated in the European IFNb-1a Dose-
Comparison Study, which was conducted to determine
whether a higher weekly dose of IM IFNb-1a could
improve upon the established efficacy of IM IFNb-1a 30
mcg in reducing the rate of sustained disability progres-
sion. Efficacy and MRI data from the first 36 months of the
study (Part 1) have been published separately.4 In sum-
mary, the effect of both doses of IFNb-1a IM seen in Part 1
of the study was similar to that observed in the pivotal
phase III trial of IFNb-1a,2 and results showed no
differences between IFNb-1a 30 mcg and 60 mcg IM on
time to sustained disability progression, extent of change
in Expanded Disability Status Scale (EDSS) score, relapse
rate, and rate of intravenous (IV) steroid use.4 In addition,
there were no statistically significant differences or trends
observed between IFNb-1a 30 mcg and 60 mcg IM with
regard to change in T2 lesion volume, change in T1 lesion
volume, number of new or enlarging T2 lesions compared
with baseline, number and volume of gadolinium-en-
hanced (Gd»/) lesions, and brain atrophy (only one MRI
parameter at one time point, i.e., the number of new or
enlarging T2 lesions at month 36 compared with month
24, showed a statistically significant difference between
the IFNb-1a 30- and 60-mcg doses [P¾/0.004]).4
Patients who completed 36 months of treatment (Part 1)
were allowed to enroll in a second phase of double-blind
treatment (Part 2). The present paper reports 48-month
efficacy data from Part 2 of the European IFNb-1a Dose-
Comparison Study.
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Dose-Comparison Study investigators.
*Correspondence: Michel Clanet, Service de Neurologie,
CHU Toulouse Purpan, Place du Docteur Baylac,
Toulouse, Cedex 31059, France.
E-mail: clanet@cict.fr
Received 7 October 2003; accepted 9 October 2003
Multiple Sclerosis 2004; 10: 139¡/144
www.multiplesclerosisjournal.com
# Arnold 2004 10.1191/1352458504ms990oa
 at LMU Muenchen on May 16, 2013msj.sagepub.comDownloaded from 
Methods
Detailed design and methodology of the study have been
published separately.5
Subjects
The European IFNb-1a Dose-Comparison Study enrolled
802 patients with a relapsing form of MS. Patients were
included in the study if they had a clinical diagnosis or a
laboratory-supported clinical diagnosis of definite MS6 for
at least one year, at least two medically documented
relapses within the three years prior to randomization,
and an EDSS score between 2.0 and 5.5, inclusive.
Patients were excluded from the study if they had
progressive disease for longer than six months, had a
relapse within two months prior to randomization, or
were pregnant or breastfeeding.
Study design
The European IFNb-1a Dose-Comparison Study was a
randomized, double-blind, parallel-group study con-
ducted throughout Europe. Patients were randomized to
receive IFNb-1a 30 mcg (n¾/402) or IFNb-1a 60 mcg (n¾/
400) IM once weekly for at least 36 months. Patients who
completed the 36-month planned study period (Part 1)
were allowed to participate in a second phase of double-
blind treatment, completing 48 months of treatment (Part
2). Thirty-four of the 38 study centres enrolled patients
into Part 2 of the study. Each study site designated a
primary examining neurologist and at least one treating
neurologist. Responsibilities of the examining neurolo-
gists included performing EDSS evaluations and neurolo-
gic examinations during all scheduled study visits; they
were not involved with any other aspect of patient care or
management. Treating neurologists were responsible for
all other aspects of patient care and management, includ-
ing the assessment and treatment of adverse events and
relapses.
The primary outcome variable was sustained disability
progression, defined as time to a sustained increase of
]/1.0 point on the EDSS persisting for six months for
patients with baseline EDSS scores of 5/4.5, or a 0.5-point
increase for patients with a baseline EDSS score of ]/5.0.
Additional efficacy outcome variables included the
following: rate of sustained progression to an EDSS
score of ]/4.0 and ]/6.0, and extent of change in EDSS.
As relapses do not fully represent the extent of disease
activity and do not correlate with disease progression,7
they were not predefined in the protocol as an efficacy
endpoint. Safety was assessed by the incidence of adverse
events and the results of blood chemistry, hematology, and
urine testing. EDSS was evaluated every three months.
Patients were seen at any time throughout the study for
the evaluation of adverse events or relapses.
Serum levels of neutralizing antibodies (NAbs) were
measured at baseline and every three months throughout
the study at a central laboratory at Biogen, Inc., using a
two-step ELISA ¡/cytopathic effect assay. We report the
incidence of titers of ]/1:20 ¡/ the level that has been
associated with reduced biologic activity of IFNb-1a.8
Statistical analysis
Analyses were based upon the intent-to-treat population
(i.e., all randomized subjects). All reported P values were
based on two-tailed statistical tests, with a significance
level of 5/0.05. No imputation was performed for missing
data.
The primary endpoint, the cumulative probability of
sustained disability progression, was calculated for each
treatment group using the Kaplan¡/Meier product-limit
method. The treatment groups were compared using the
Cox proportional hazards model using baseline EDSS
score, prestudy relapse rate, duration of disease, age, and
gender as preplanned covariates. Covariates, which did
not reach a significance level of 0.05, were dropped from
the Cox proportional hazards model. All time-to-event
endpoints were analysed in a similar way. The treatment
difference on the extent of change in EDSS was analysed
using the rank-based analysis of covariance (ANCOVA)
model at each predefined time point using the baseline
EDSS score as the covariate. Annualized relapse rates
were compared between doses using the likelihood ratio
test for a Poisson model. Percentages of relapse-free
patients were estimated using the Kaplan¡/Meier method,
and the difference between treatment groups was com-
pared using the log-rank test.
Results
Subjects
Six hundred and eight subjects completed 36 months on
study in Part 1. As some centres decided not to participate
in the extension study, only 493 patients were enrolled in
Part 2 (Figure 1). A total of 446 subjects (56%) of the initial
cohort who entered Part 2 of the study completed 48
months of treatment and follow-up (Figure 1). The
proportion of subjects enrolled in Part 2 who discontinued
the study before 48 months was 13% (31/246) in the 30-
mcg group and 6% (16/247) in the 60-mcg group. The most
common reasons for study discontinuation in both the 30
and 60-mcg groups were perceived worsening of disease
(6% [14/246] and 2% [6/247], respectively), other reasons
(4% [11/246] and 2% [6/247], respectively), and adverse
events or lack of tolerability to study drug (1% [3/246] and
B/1% [1/247], respectively). The ‘other’ category included
patient request and the wish to become pregnant. The
median time on study was 1447 days (3.96 years) in the
30-mcg group and 1455 days (3.99 years) in the 60-mcg
group.
The baseline demographic and clinical characteristicsof
patients who were originally enrolled in the study are
listed in Table 1. There were no differences between
treatment groups with regard to age, sex, race, disease
duration, EDSS scores, MRI, or prestudy relapse rates.
Overall, the mean age at diagnosis of MS was 31.3 years,
the mean disease duration was 6.4 years, and the mean
EDSS was 3.6 at study entry. The mean relapse rate during
the three years prior to enrollment was 1.3 per year. As
shown in Table 1, baseline characteristics of patients
included in Part 2 were similar to baseline characteristics
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of patients included in Part 1, suggesting that there was no
selection bias to affect the clinical results of patients
included in Part 2 who were followed for up to four years.
Disability progression
The cumulative percentage of subjects with sustained
disability progression for each treatment group is shown
in Figure 2. After 48 months of treatment, the cumulative
rate of sustained disability progression was not different
between the IFNb-1a 30-mcg group and the 60-mcg IM
group. The cumulative percentage of subjects who pro-
gressed at 48 months was 48% in the IFNb-1a 30-mcg
group and 43% in the 60-mcg group (rate ratio, 0.94; 95%
confidence interval [CI], 0.75¡/1.17; P¾/0.58).
The cumulative percentage of subjects who progressed
to an EDSS score of ]/4.0 or ]/6.0 was analysed. There
Figure 1 Pro le of patients in Part 1 and Part 2 of the European IFNb-1a Dose-Comparison Study.
Table 1 Baseline demographic and clinical characteristics of patients enrolled in Part 1 and Part 2 of the European IFNb-1a Dose-
Comparison Study
Characteristic Part 1 Part 2
All patients IFNb-1a 30 mcg IFNb-1a 60 mcg
n¾/802 n¾/246 n¾/247
Age (years)
Mean9/SD 36.89/7.9 37.69/7.7 36.99/7.9
Gender (% female) 68 69 68
Ethnicity (% Caucasian) 97 98 98
Classification of MS (%)
Relapsing¡/remitting 85 86 87
Relapsing¡/progressivea 15 14 13
Age at diagnosis (years)
Mean9/SD 31.39/7.8 31.99/7.8 31.69/7.7
EDSS score
Mean9/SD 3.69/1.0 3.49/1.0 3.59/1.0
Prestudy relapse rateb
Mean9/SD 1.39/0.6 1.39/0.6 1.39/0.5
SD, standard deviation.
aPatients with early progressive disease who experienced relapses; patients with confirmed progressive disease and no relapses were
excluded from the study.
bRelapse rate per year during the three years prior to study enrollment.
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were no significant differences between treatment groups
for either endpoint (rate ratio for EDSS ]/4.0, 1.01; 95%
CI, 0.70¡/1.45; P¾/0.96; rate ratio for EDSS ]/6.0, 0.96;
95% CI, 0.69¡/1.32; P¾/0.79). By month 48, 30%
of subjects in each group progressed to an EDSS score of
]/4.0 and 22% of subjects in each group progressed to an
EDSS score of ]/6.0. At month 48, the mean change in
EDSS score was 0.30 in the 30-mcg group and 0.30 in the
60-mcg group; no significant differences between treat-
ment groups were observed in change in EDSS score at
month 12 (P¾/0.86), month 24 (P¾/0.99), month 36
(P¾/0.47), or month 48 (P¾/0.69) (Table 2).
Disability progression was also analysed according to
disease characteristics at baseline, including EDSS score
(5/3.5 or ]/4.0), presence of Gd»/ lesions (0 or ]/1), and
type of relapsing MS (relapsing¡/remitting or relapsing¡/
progressive). There were no differences between IFNb-1a
30 mcg and 60 mcg for subjects with baseline EDSS scores
of 5/3.5 (hazard ratio, 0.84; 95% CI, 0.61¡/1.16; P¾/0.29)
or baseline EDSS scores of ]/4.0 (hazard ratio, 1.04; 95%
CI, 0.76¡/1.42; P¾/0.80). The proportions of subjects with
baseline EDSS scores of 5/3.5 who had disability progres-
sion by 48 months were 40% in the IFNb-1a 30-mcg group
and 34% in the 60-mcg group. The proportions of subjects
with baseline EDSS scores of ]/4.0 who had disability
progression by 48 months were 51% in the 30-mcg group
and 53% in the 60-mcg group. Subgroup analyses based
on presence (hazard ratio, 0.99; 95% CI, 0.66¡/1.48;
P¾/0.94) or absence (hazard ratio, 0.80; 95% CI, 0.49¡/
1.31; P¾/0.38) of Gd»/ lesions at baseline also showed
no significant difference between IFNb-1a 30 mcg and 60
mcg on progression of disability. In addition, there were
no differences between IFNb-1a doses on progression of
disability in subjects with relapsing¡/remittingMS (hazard
ratio, 0.95; 95% CI, 0.74¡/1.22; P¾/0.66) or relapsing¡/
progressive MS (hazard ratio, 0.89; 95% CI, 0.55¡/1.45;
P¾/0.63).
An analysis was conducted to determine whether the
presence or frequency of relapse would differentially
affect disability progression in the IFNb-1a 30 mcg
and 60 mcg groups. Results showed no significant
differences between IFNb-1a 30 mcg and 60 mcg on
disability progression in patients who experienced no
relapses (P¾/0.20), ]/1 relapse (P¾/0.82), or ]/3 relapses
(P¾/0.93).
Figure 2 Kaplan¡/Meier curve of the cumulative probability of disability progression by treatment group (all subjects). The cumulative
probability of developing disability progression was similar between the IFNb-1a 30-mcg group and 60-mcg group (P¾/0.58).
Table 2 Extent of change in EDSS scores from baseline over four





n¾/402 n¾/400 P value
Mean change9/SEM
Months 0¡/12 0.099/0.04 0.069/0.04 0.86
n¾/376 n¾/376
Months 0¡/24 0.149/0.05 0.169/0.05 0.99
n¾/347 n¾/348
Months 0¡/36 0.259/0.06 0.279/0.06 0.47
n¾/328 n¾/326
Months 0¡/48 0.309/0.08 0.309/0.08 0.69
n¾/192 n¾/211
SEM, standard error of the mean.
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Relapses
Relapse-related data were collected as part of the doc-
umentation of adverse events, and relapse rate was not a
predefined efficacy endpoint in the study; hence, relapse
rate is not a reliable efficacy endpoint. During Part 1 of the
study, the mean annualized relapse rate based on self
reports over 36 months of treatment was 0.77 in the 30-
mcg group and 0.81 in the 60-mcg group (P¾/0.330, 30
mcg versus 60 mcg). Over 48 months of treatment, the
mean annualized relapse rate was 0.75 in the 30-mcg
group and 0.77 in the 60-mcg group (P¾/0.527, 30 mcg
versus 60 mcg); relapses tended to decrease over the 48
months. There were no differences between treatment
groups in mean self-reported relapse rates during each
year. Over the 48 months of treatment, the percentage of
relapse-free patients was 18% in the IFNb-1a 30-mcg
group and 19% in the 60-mcg group (no significant
difference [P¾/0.829]). The median time to first relapse
was 402 days in the 30-mcg group and 347 days in the 60-
mcg group (P¾/0.822, 30 mcg versus 60 mcg). The rate of
IV steroid use, a surrogate marker for severe relapses, was
0.66 courses per subject per year in the 30-mcg group and
0.67 in the 60-mcg group after 48 months of treatment.
Safety
Both doses of IFNb-1a were well tolerated over 48 months
of treatment. Overall, the safety profile of IFNb-1a was
consistent with that observed in other clinical studies and
from post-marketing surveillance. The most common
treatment-related adverse events in both dose groups
were flu-like syndrome, MS exacerbation, asthenia, de-
pression, pharyngitis, and headache. Of all treatment-
related adverse events that occurred in ]/10% of patients,
a difference of more than 5% was identified between the
groups with regard to the percentage of patients with
arthralgia, hypertonia, and infection (each occurred more
often in the 30-mcg group) and flu-like syndrome, which
occurred significantly more often (P¾/0.016) in the 60-
mcg group.
Neutralizing antibodies
The proportions of patients who had NAbs (titers ]/20
LU/mL) at any time during the study were 2.3% in the 30-
mcg group and 5.8% in the 60-mcg group (P¾/0.011).
Discussion
Results from Part 2 of the European IFNb-1a Dose-
Comparison Study demonstrated that the clinical efficacy
of IFNb-1a 30 mcg and 60 mcg IM is equivalent and is
sustained for up to 48 months of treatment. There were no
significant differences between the two IFNb-1a doses on
any of the clinical endpoints, including sustained dis-
ability progression (including subgroup analyses of dis-
ability progression), extent of change in EDSS score, and
relapse rate. Although relapse rate was not a predefined
efficacy endpoint in the study, data on relapses were
collected as part of the documentation of adverse events.
As such, self-reported neurologic symptoms that did not
necessarily fulfill the usual criteria for a relapse (typically
included in relapse-based protocols) were reported
throughout the study. Hence, the rates of relapse for
each group reported in this paper were likely overesti-
mated. Relapse rate is reported here because it is typically
reported as an outcome measure in clinical trials of MS.
However, sustained progression in EDSS is a better
measure of disease activity, particularly in long-term
studies.
The proportion of patients who discontinued treatment
because of perceived worsening of disease was higher in
the 30-mcg group (6%) compared with the 60-mcg group
(2%). It is important to note that this measure of worsen-
ing of disease was not always supported by neurologic
examination ¡/ in some cases, it was simply a ‘feeling’ the
patient had. To further explore this issue, a Kaplan¡/Meier
analysis was conducted on a combined endpoint of
discontinuation because of perceived worsening of dis-
ease or sustained disability progression (]/1.0 point on
EDSS). There was no statistically significant difference
between IFNb-1a 30 mcg and 60 mcg (P¾/0.54); therefore,
it is likely that no bias was introduced due to differences
in rates of discontinuation based on perceived worsening
of disease.
Although the incidence of NAbs was significantly
higher in the 60-mcg dose group (5.8%) compared with
the 30-mcg dose group (2.3%), the incidence was low in
both treatment groups. This result suggests that higher
doses of IFNb may produce higher incidences of NAbs;
however, this issue is still a matter of debate due to
inconsistent results among studies.3,8,9 The development
of NAbs to IFNb products has been associated with
reduced clinical efficacy in some studies.10¡ 12The impact
of NAbs on the efficacy of IFNbs in these studies was
observed after 18 months and two years, suggesting that
long-term follow-up is important for an accurate assess-
ment of efficacy in patients with MS.
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